Taichung

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Asthma5 trials
• Hepatitis B5 trials
• COPD2 trials
• Multiple myeloma2 trials
• Head and neck cancer1 trial

Phase

• Phase 310 trials
• Phase 24 trials
• Phase 41 trial

Status

• Completed8 trials
• Recruiting4 trials
• Active, not recruiting3 trials

Lead sponsor

• GlaxoSmithKline15 trials

Running trials

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

  Contact: Ming-Cheng Chan (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Po-Hsien Li (principal investigator)

• Active, not recruiting

  A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

  NCT06537414· Phase 2· GlaxoSmithKline· Source

• Recruiting

  Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

  NCT06979323· Phase 3· GlaxoSmithKline· Source

  Contact: Ming-Cheng Chan (principal investigator)

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Ching-Yun Hsieh (principal investigator)

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• COPD1 recruiting
• Head and neck cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

  NCT05276297· Phase 2· GlaxoSmithKline· Source

• Completed

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· Phase 2· GlaxoSmithKline· Source

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source